Cemdisiran by Alnylam Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval

Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

Boosting physical fitness in youth linked to lower mental disorder risks

Study revealed that higher levels of cardiorespiratory fitness, muscular endurance, and muscular power in children and adolescents significantly lower the risks of developing anxiety, depression,

May 1, 2024

How to take care of trans patients in hospice

In the United States, more than 1.6 million people identify as transgender. Of these, more than one-fifth are over the age of 65, the vast

August 22, 2023

Surgeon General Calls for Social Media to Carry Cigarette-Like Warning Labels

The U.S. surgeon general has called on Congress to require warning labels on social media platforms similar to those now mandatory on cigarette boxes. In

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.